Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2016 - 2025)

Cumberland Pharmaceuticals' Cash from Financing Activities history spans 16 years, with the latest figure at -$681738.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 50.54% year-over-year to -$681738.0; the TTM value through Dec 2025 reached -$6.7 million, down 3525.79%, while the annual FY2025 figure was -$6.7 million, 3525.79% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$681738.0 at Cumberland Pharmaceuticals, down from -$386879.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.9 million in Q1 2022 and bottomed at -$5.5 million in Q1 2025.
  • The 5-year median for Cash from Financing Activities is -$735300.0 (2021), against an average of -$820180.6.
  • The largest YoY upside for Cash from Financing Activities was 401.86% in 2022 against a maximum downside of 619.86% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$735300.0 in 2021, then plummeted by 278.19% to -$2.8 million in 2022, then soared by 36.02% to -$1.8 million in 2023, then increased by 22.53% to -$1.4 million in 2024, then soared by 50.54% to -$681738.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Cash from Financing Activities are -$681738.0 (Q4 2025), -$386879.0 (Q3 2025), and -$150797.0 (Q2 2025).